Search clinical trials for: REGN2810/ipi

Total 2218 results

Regeneron Pharmaceuticals
Sanofi

Terminated

A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer

Advanced Non-Small Cell Lung Carcinoma

United States, Belgium, France, Germany, Korea, Republic of, Poland, Spain, Taiwan, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Terminated

REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

Non-small Cell Lung Cancer

United States, Italy, Lithuania
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Non-small Cell Lung Cancer

United States, France, Korea, Republic of, Italy, Austria, China, Georgia, Greece, Ireland, Lithuania, Malaysia, Poland, Romania, Russian Federation, Slovakia, Thailand, Turkey, Ukraine
University of Primorska
Biostile d.o.o.

Completed

Clinical Trials of Five Different Food Supplements With Restriction Diet in Adults (FOODSU)

Inflammation | Hypertension | Hypercholesterolemia | Overweight and Obesity

Slovenia
Regeneron Pharmaceuticals

Available

Expanded Access Use of Cemiplimab in Patients With Solid Tumors
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery

Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck | Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage...

United States
Regeneron Pharmaceuticals

Active, not recruiting

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Advanced Non-small Cell Lung Cancer

United States
Nutrition Institute, Slovenia
Vizera d.o.o.; ADM, Ambulanta družinske medicine, Ljubljana, Slovenia; Adrialab... and other collaborators

Completed

Comparative Single-dose Bioavailability Study of Different CoQ10 Formulations

Bioavailability of Coenzyme Q10

Slovenia
SecuraBio

Completed

Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145

Healthy

United States
Medtronic - MITG

Completed

Determination of the Clinical Impact of Continuous Surveillance Monitoring (SM) and Utility of IPI. (IPI)

Respiratory Insufficiency | Respiratory Depression

United States
Regeneron Pharmaceuticals

Completed

Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)

Diabetic Macular Edema | Neovascular Age-Related Macular Degeneration

United States
SecuraBio

Completed

Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects (IPI-145-14)

Hepatic Impairment

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute; Infinity Pharmaceuticals, Inc.

Terminated

IPI-504 in NSCLC Patients With ALK Translocations

Lung Cancer | Stage IV Lung Cancer | Stage IIIb Lung Cancer

United States
Infinity Pharmaceuticals, Inc.

Completed

Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)

Gastrointestinal Stromal Tumors | Soft Tissue Sarcomas

United States, Canada
SecuraBio

Completed

A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects

Asthma

Germany, United Kingdom
Nutrition Institute, Slovenia
Slovenian Research Agency; Valens Int. d.o.o., Slovenija; Community Health Centre...

Completed

The Effect of Content of Barley Beta-glucans in Bread on Postprandial Blood Sugar (ARRS-bGL-01)

Glycemic Index

Slovenia
Ezra Cohen
The V Foundation for Cancer Research

Recruiting

Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | HPV-Related Malignancy | Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma | HPV-Related Carcinoma | HPV-Related Squamous Cell Carcinoma | Head and Neck Cancer Stage IV | Head and Neck Cancer Stage III

United States
Infinity Pharmaceuticals, Inc.

Terminated

A Phase 1 Dose Escalation Study of IPI-493

Advanced Malignancies

United States
Infinity Pharmaceuticals, Inc.

Withdrawn

Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma

Dedifferentiated Liposarcoma

United States
Infinity Pharmaceuticals, Inc.

Completed

Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma (IPi-504-01)

Multiple Myeloma

United States
Rush University Medical Center

Completed

Early Identification and Prevention of Extubation Failure in Adults Using Integrated Pulmonary Index (IPI)

Mechanical Ventilation Complication | Extubation

United States
SecuraBio

Completed

IPI-145 ADME and Absolute Bioavailability Study

Healthy

Netherlands
Infinity Pharmaceuticals, Inc.

Terminated

A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma

Metastatic Melanoma

United States
Infinity Pharmaceuticals, Inc.

Completed

Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)

Lung Cancer

United States
National Institute of Allergy and Infectious Diseases...
Regeneron Pharmaceuticals

Terminated

Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART

HIV Infections

United States
Regeneron Pharmaceuticals

Terminated

Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

United States
SecuraBio

Terminated

A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies

Hematologic Malignancies

United States
Infinity Pharmaceuticals, Inc.

Completed

IPI-926 Extension Protocol for Continuation of Treatment With IPI-926

Chondrosarcoma | Basal Cell Carcinoma

United States
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma

Cutaneous Squamous Cell Carcinoma

United States, Germany, Australia
Regeneron Pharmaceuticals
Sanofi

No longer available

Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals

Recruiting

A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Metastatic Castration-resistant Prostate Cancer (mCRPC) | Clear Cell Renal Cell Carcinoma (ccRCC)

United States
Regeneron Pharmaceuticals
Sanofi

Recruiting

Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

Basal Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
Regeneron Pharmaceuticals
BioNTech SE

Recruiting

Safety and Efficacy of Intravenous Cemiplimab Plus BNT116 Versus Cemiplimab Alone in Advanced Non-Small Cell Lung Cancer in Adult Participants With PD-L1 ≥ 50%

Advanced Non-Small Cell Lung Cancer

United States, Korea, Republic of, Spain, Georgia, Taiwan, Germany, Turkey
Regeneron Pharmaceuticals

Recruiting

Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies

Squamous Cell Carcinoma of Head and Neck

United States, Spain
Sidney Kimmel Comprehensive Cancer Center at Johns...
Regeneron Pharmaceuticals

Not yet recruiting

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

Colorectal Cancer

United States
University of Miami
Regeneron Pharmaceuticals

Withdrawn

Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Squamous Cell Carcinoma | HNSCC | Squamous Cell Carcinoma of the Larynx | Squamous Cell Carcinoma of the Oral Cavity | Squamous Cell Carcinoma of Hypopharynx
SecuraBio

Completed

A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)

Indolent Non-Hodgkin Lymphoma

Belgium, France, Italy, Spain, Canada, United States, Bulgaria, United Kingdom, Hungary, Georgia, Belarus, Czechia
Infinity Pharmaceuticals, Inc.

Completed

A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma

Conventional Chondrosarcoma

United States, Italy, Canada, Austria, Australia, Germany, France, Netherlands, Norway, Poland, Russian Federation, Sweden, United Kingdom
Regeneron Pharmaceuticals

Withdrawn

Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study

Advanced Malignancies

United States
Regeneron Pharmaceuticals

Recruiting

A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab

Advanced Solid Tumor | Metastatic Solid Tumor

Netherlands
Regeneron Pharmaceuticals
ISA Pharmaceuticals B.V.

Active, not recruiting

Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

Cervical Cancer

Spain, Korea, Republic of, Netherlands, Brazil, Belgium, United States, Italy, Russian Federation
Regeneron Pharmaceuticals

Not yet recruiting

Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)

Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Sanofi

Recruiting

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Cutaneous Squamous Cell Carcinoma

United States, Australia, Spain, Germany, Belgium, Italy, France, Japan, United Kingdom, Brazil, Canada, Greece, Ireland, New Zealand, Poland, Russian Federation
Regeneron Pharmaceuticals

Completed

Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Advanced Cutaneous Squamous Cell Carcinoma

United States, Spain, France, Italy, Australia, Germany, Brazil, Greece
Regeneron Pharmaceuticals

Active, not recruiting

CemiplimAb Survivorship Epidemiology (CASE)

Basal Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States, Puerto Rico
Regeneron Pharmaceuticals
Sanofi

Completed

PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

Carcinoma, Basal Cell

United States, Canada, France, Italy, Spain, Germany, Belgium, Austria, Greece, Switzerland
Regeneron Pharmaceuticals
Sanofi

Completed

An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)

Melanoma

Korea, Republic of, Serbia, Netherlands, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Completed

An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)

Recurrent Squamous Cell Carcinoma of Head | Recurrent Squamous Cell Carcinoma of Neck | Metastatic Squamous Cell Carcinoma of Head | Metastatic Squamous Cell Carcinoma Neck

Korea, Republic of, United Kingdom
Infinity Pharmaceuticals, Inc.

Completed

A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies

Neoplasms

United States, Canada
AbbVie
Infinity Pharmaceuticals, Inc.

Completed

Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma

Lymphoma

Japan

Search clinical trials for: REGN2810/ipi

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations